Skip to main content
RXST
NASDAQ Industrial Applications And Services

RxSight Q3 Revenue Falls 19% to $24.6M; Net Loss Widens to $16.2M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$4.59
Mkt Cap
$190.913M
52W Low
$4.4
52W High
$13.22
52W Position info
4.3% above low
Off High info
65% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

RXST is trading near its 52-week low of $4.4 (4.3% above the low).

Summary

RxSight posted Q3 revenue of $24.6 million, down 19%, a wider net loss of $16.2 million, and gross margin of 73.6%, while holding $254.7 million in cash and investments.


Key Events · Earnings and Guidance · RXST

  • Q3 Revenue Down 19% to $24.6M

    Total revenue of $24.6 million versus $30.3 million a year ago, driven by 23,128 LAL units and ongoing competitive pressures; Alcon collaboration revenue was minimal at $40 thousand.

  • Net Loss Widens to $16.2M

    Net loss of $(16.2) million, or $(0.39) per share, versus $(9.8) million, or $(0.24) per share in Q3 2025; adjusted net loss was $(8.6) million, or $(0.21) per share.

  • Gross Margin Slips to 73.6%

    Down from 79.9% a year ago on higher inventory reserves and higher LAL and LDD inventory costs, partly offset by favorable product mix.

  • $254.7M Cash After Alcon Payment

    Cash, cash equivalents and short-term investments totaled $254.7 million at September 30, 2026, including the $60 million received in the quarter from the Alcon collaboration.


Analysis · RXST · Industrial Applications And Services

Revenue fell 19% year over year to $24.6 million as competitive pressure kept eroding LAL/LDD demand, and gross margin dropped to 73.6% from 79.9% on inventory reserves and higher lens and device costs. The net loss widened to $16.2 million from $9.8 million, so the restructuring and near-doubling of the sales force have not yet shown up in the numbers. The offset is liquidity: $254.7 million of cash and investments, including $60 million from Alcon, funds the turnaround push, but a new $50.0 million refund liability on the balance sheet is a claim on that cash that needs explaining. With the stock near its 52-week low, this print keeps the burden of proof on management's commercial rebuild.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RXST was trading at $4.59 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $190.9M. The 52-week trading range was $4.40 to $13.22. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RXST - Latest Insights

RXST
Nov 03, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.92
Real-time Price: $4.58 info
Change: +$0.660 (+17%) info
Market Cap: $192.036M info
RXST
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.59
Real-time Price: $4.58 info
Change: -$0.0100 (-0.22%) info
Market Cap: $192.036M info
RXST
Aug 10, 2026, 8:01 AM EDT
Filing Type: SC TO-I
Importance Score:
7
Price at Filing: $6.26
Real-time Price: $4.58 info
Change: -$1.68 (-27%) info
Market Cap: $192.036M info
RXST
Jul 15, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.25
Real-time Price: $4.58 info
Change: -$0.670 (-13%) info
Market Cap: $192.036M info
RXST
Jul 06, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.54
Real-time Price: $4.58 info
Change: -$0.960 (-17%) info
Market Cap: $192.036M info